Global Chronic Plaque Psoriasis Market, Global Chronic Plaque Psoriasis Market Report, Global Chronic Plaque Psoriasis Market Trends, Global Chronic Plaque Psoriasis Market Size

Global Chronic Plaque Psoriasis Market Analysis 2025–2029: Opportunities for Strategic Growth

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Chronic Plaque Psoriasis Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The market for chronic plaque psoriasis has seen substantial growth in recent years. It is anticipated to expand from $20.79 billion in 2024 to $22.26 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.0%. This past growth can be ascribed to an increasing prevalence of psoriasis, a rise in co-morbidities, advantageous reimbursement policies, elevated alcohol and smoking consumption, and the development of telemedicine.

The chronic plaque psoriasis market is projected to undergo significant expansion in the coming years, with its size anticipated to reach $29.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.9%. This forecasted growth is primarily driven by factors such as the rising or declining prevalence of cpp globally, an increase in autoimmune diseases, growing healthcare budgets, an aging population, and a heightened demand for effective treatments. Key trends influencing this period include advancements in biologic treatments, the development of oral small molecule inhibitors, greater integration of digital health, personalized medicine approaches, and the introduction of biosimilars.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Which Drivers Are Shaping The Chronic Plaque Psoriasis Industry’s Market Share?

A projected increase in immune system dysfunction cases is anticipated to drive the expansion of the chronic plaque psoriasis market. Immune system dysfunction describes a state where the immune system fails to function effectively, making individuals more susceptible to infections, autoimmune diseases, and cancer. The growing incidence of immune system dysfunction is linked to factors such as genetic predispositions, environmental triggers, poor nutrition, sustained stress, and the rising occurrence of autoimmune conditions and infections like HIV. Managing immune system dysfunction necessitates treatment for chronic plaque psoriasis, as the immune system mistakenly triggers an excessive proliferation of skin cells, leading to inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, a US-based nonprofit organization, reported that over 8 million Americans are impacted by psoriasis. Globally, the condition affects 125 million individuals, representing 2 to 3% of the total population. Thus, the escalating cases of immune system dysfunction are propelling the growth of the chronic plaque psoriasis market.

How Is The Chronic Plaque Psoriasis Market Classified Into Different Segments?

The chronic plaque psoriasismarket covered in this report is segmented –

1) By Drug Class: Biologics; Small Molecule Drugs

2) By Route Of Administration: Injectable; Oral; Topical

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others

How Are Trends Influencing The Chronic Plaque Psoriasis Market?

Major companies operating within the chronic plaque psoriasis market are concentrating on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to achieve advancements in managing chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that function by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, thereby reducing inflammation in autoimmune conditions like chronic plaque psoriasis. For example, in October 2023, UCB S.A., a biopharmaceutical company from Belgium, announced that the U.S. Food and Drug Administration (FDA) had granted approval for BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Bimekizumab is the first approved medication for psoriasis specifically designed to target and inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines contributing to inflammatory processes. Its approval was founded on evidence gathered from three Phase 3 multicenter trials—BE READY, BE VIVID, and BE SURE—which collectively assessed its safety and efficacy across 1,480 patients with moderate to severe plaque psoriasis.

Which Industry Leaders Are Driving Innovation Across The Chronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Geographies Are Emerging As Strong Markets For The Chronic Plaque Psoriasis Industry?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Plaque Psoriasis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2025, By The Business Research Company

Psoriasis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795